Most diabetes medications treat the symptom — high blood glucose — rather than the underlying cause: insulin resistance. Several commonly prescribed diabetes drugs carry serious risks that are systematically understated.

The Problem with Treating Symptoms

Type-2 diabetes is caused by insulin resistance. The logical treatment is to reduce insulin resistance — through diet, fasting, and exercise. Instead, conventional medicine treats the symptom (high blood glucose) with drugs that often make the underlying insulin resistance worse.

Insulin Therapy

Insulin therapy for type-2 diabetes is particularly problematic. Insulin is a growth hormone that drives fat storage and cell proliferation. Giving insulin to a patient with insulin resistance:

  • Worsens insulin resistance over time
  • Causes weight gain (which worsens insulin resistance further)
  • Increases cancer risk (insulin is a growth factor)
  • Causes hypoglycemia (dangerously low blood sugar)

Treating type-2 diabetes with insulin is like treating alcoholism with more alcohol. It addresses the symptom while worsening the disease.

Sulfonylureas

Sulfonylureas (glipizide, glyburide, glimepiride) stimulate the pancreas to produce more insulin. They:

  • Cause weight gain
  • Cause hypoglycemia
  • Exhaust the pancreatic beta cells, accelerating disease progression
  • Have no evidence of reducing cardiovascular mortality

SGLT2 Inhibitors

SGLT2 inhibitors (empagliflozin, canagliflozin) work by causing the kidneys to excrete glucose in the urine. They have shown cardiovascular and renal benefits in high-risk patients. However, they also cause:

  • Urinary tract infections
  • Genital mycotic infections
  • Diabetic ketoacidosis (rare but serious)
  • Amputations (canagliflozin)

Metformin: The Exception

Metformin is the one diabetes drug with a reasonable evidence base. It reduces hepatic glucose production, improves insulin sensitivity, and has shown modest cardiovascular benefits. It is cheap, generic, and has been used for 60 years. It is the appropriate first-line drug if dietary intervention alone is insufficient.

The Bottom Line

Diet should be the first-line treatment for type-2 diabetes. Multiple studies demonstrate that dietary intervention can achieve complete remission in 50-80% of patients. Medications should be reserved for patients who fail dietary treatment — and even then, the choice of medication matters enormously.